Source: Australian Therapeutic Goods Administration
Vocabria should be prescribed by a physician experienced in the management of human immunodeficiency virus (HIV) infection.
Vocabria is indicated for the treatment of HIV-1 in combination with rilpivirine, therefore, the product information for rilpivirine should be consulted for recommended dosing.
Oral lead-in dosing
Vocabria tablets are recommended for approximately one month (at least 28 days) in virologically suppressed patients prior to the initiation of cabotegravir injections, a component of Cabenuva (cabotegravir and rilpivirine prolonged release suspensions for injection), to assess tolerability to cabotegravir. One Vocabria tablet (30 mg) should be taken with one rilpivirine tablet (25 mg) once daily.
The final oral dose should be taken on the same day injections with Cabenuva are started.
No dose adjustment is required in elderly patients. There are limited data available on the use of cabotegravir in patients aged 65 years and over (see Section 5.2 Pharmacokinetic Properties, Special Patient Populations in the Product Information).
For further information refer to the Product Information.